Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. It engages in the business of developing and commercializing novel therapeutics based on ribonucleic acid interference. The company was founded by Noble Laureate, David Bartel, Thomas Tuschl, Phillip Zamore, Paul R. Schimmel, and Phillip Allen Sharp on June 14, 2002 and is headquartered in Cambridge, MA.
Sector:
Health Technology
Industry:
Pharmaceuticals Major
Employees:
2,230
Frequently Asked Questions
What is Market Cap of Alnylam Pharmaceuticals Inc?
Market cap, also known as market capitalization, is the total market value of a company. It’s calculated by multiplying the current market price by the total number of shares outstanding. Alnylam Pharmaceuticals Inc market cap is $59.25B.
What is the 52-week high for Alnylam Pharmaceuticals Inc?
52 week high is the highest price of a stock in the past 52 weeks, or one year. Alnylam Pharmaceuticals Inc 52 week high is $469.81 as of September 07, 2025.
What is the 52-week low for Alnylam Pharmaceuticals Inc?
52 week low is the lowest price of a stock in the past 52 weeks, or one year. Alnylam Pharmaceuticals Inc 52 week low is $205.87 as of September 07, 2025.
What is Alnylam Pharmaceuticals Inc stock price today?
Alnylam Pharmaceuticals Inc stock price today is $452.00.
What was Alnylam Pharmaceuticals Inc stock price yesterday?
Alnylam Pharmaceuticals Inc stock price yesterday was $453.54.
What is the PE ratio of Alnylam Pharmaceuticals Inc?
The Price-to-Earnings (or P/E) ratio is a commonly used tool for valuing a company. It’s calculated by dividing the current share price by the earnings per share (or EPS). It can also be calculated by dividing the company’s Market Cap by the Net Profit. Alnylam Pharmaceuticals Inc’s P/E ratio is -183.22.
What is the Price-to-Book ratio of Alnylam Pharmaceuticals Inc?
The Price-to-Book (P/B) ratio is a commonly used tool for valuing a company. It’s calculated by dividing a company’s market capitalization by its book value. Alnylam Pharmaceuticals Inc P/B ratio is 236.2485.
What is the 50-day moving average of Alnylam Pharmaceuticals Inc?
The 50-day moving average is a frequently used data point by active investors and traders to understand the trend of a stock. It’s calculated by averaging the closing stock price over the previous 50 trading days. Alnylam Pharmaceuticals Inc 50-day moving average is $384.73.
How many employess does Alnylam Pharmaceuticals Inc has?